XML 74 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Stock Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Stock-based compensation expense   $ 47,377   $ 102,892 $ 88,627 $ 132,090
Stock-based compensation expenses   $ 47,400   $ 102,900    
Grants, Stock options   54,575   207,583 1,084,924 1,499,120
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award         550,110 options relating to the Unvested Tranche met the conditions for vesting as the average closing price of the Company's common stock exceeded $128.65 during 20 consecutive trading days in March 2023 and the compound annual growth rate of the Company's common stock exceeded that of the Nasdaq Biotech Index by greater than 5%  
Chief Executive Officer            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Stock-based compensation expenses         $ 12,800  
Grants, Stock options 3,300,000          
Minimum [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Compound annual growth rate         5.00%  
Unvested Tranche Member            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Stock-based compensation expenses         $ 88,600 $ 132,100
Incremental compensation cost         $ 600  
Vesting, Stock options         550,110  
Average closing price     $ 128.65      
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award     550,110 options relating to the Unvested Tranche met the conditions for vesting as the average closing price of the Company's common stock exceeded $128.65 during 20 consecutive trading days in March 2023 and the compound annual growth rate of the Company's common stock exceeded that of the Nasdaq Biotech Index by greater than 5%.      
Unvested Tranche Member | Chief Executive Officer            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Stock-based compensation expenses   $ 4,400